Medtronic Posts Strong Fiscal 2026 Growth and Free Cash Flow
Medtronic reported fiscal 2026 revenue growth of 8.4% (5.8% organic) to $36.4 billion, its strongest top-line growth in a decade. Free cash flow rose 4.6% to $5.43 billion as the company restructured to free cash for dividends while expanding higher-growth cardiovascular and neuroscience businesses. Analysts project 14% EPS CAGR from fiscal 2026-2029.